Latest HER2/neu Stories
Median progression-free survival of 7.6 months reported for overall study population whose disease has progressed on a median of 4 prior therapies CAMBRIDGE, Mass., April 20, 2015 /PRNewswire/
NEW DELHI, April 20, 2015 /PRNewswire/ -- - Development of a Novel Taxane and a PI3K Targeting Supramolecular Therapeutic Using the VOLVOX Platform - To be Presented on
LONDON, April 16, 2015 /PRNewswire/ -- SummaryGBI Research, the leading business intelligence provider, has released its latest research, ''Breast Cancer Therapeutics in Major
DURHAM, N.C., April 16, 2015 /PRNewswire-iReach/ -- The majority of gastric cancers harbor genomic alterations (GAs) associated with potential benefit from targeted therapies, according to a
A longstanding problem in cancer research is the lack of usable DNA remaining in post-processed tissues.
LONDON, April 9, 2015 /PRNewswire/ -- This report on cancer diagnostics analyzes the current as well as future prospects of various facets of the market in detail.
Study Results Highlight Molecular Similarities and Differences between Uterine Papillary and Ovarian Serous Carcinomas, and between Epithelial Ovarian and Endometrial Cancers IRVING,
Phase 1 study of MM-302 will be presented in a plenary oral session CAMBRIDGE, Mass., March 26, 2015 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.
- a study of the individuals in a group of people within a specific context and their relationships.
- In rhetoric, the description of any one's personal appearance.